Experienced in Hairy Cell Leukemia (HCL)

Georg Stussi

Bellinzona, TI, CH 
Experienced in Hairy Cell Leukemia (HCL)
Bellinzona, TI, CH 
OverviewLocationsClinical Research

Overview

Georg Stussi practices in Bellinzona, Switzerland. Mr. Stussi is rated as an Experienced expert by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Leukemia, Marginal Zone Lymphoma (MZL), Chronic B-Cell Leukemia (CBCL), Tissue Biopsy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 100 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hairy Cell Leukemia (HCL).

Gender
Male

Locations

Bellinzona, TI, Switzerland
Other Locations
Lugano, TI, Switzerland
Bern, BE, Switzerland
Switzerland
Zurich, ZH, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drugs: Peginterferon ?2b, Nilotinib
Study Phase: Phase 3
View 1 Less Clinical Trial

100 Total Publications

Respiratory Syncytial Virus Vaccination in Adult Allogeneic Hematopoietic Cell Transplant Recipients.
Respiratory Syncytial Virus Vaccination in Adult Allogeneic Hematopoietic Cell Transplant Recipients.
Journal: JAMA
Published: October 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Stussi's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 21 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile